Life Biosciences tests cellular reprogramming in a human eye
David Sinclair's longevity company has moved ER-100 from animal work into a small FDA trial for glaucoma and optic nerve disease.
By Ryan Merket ยท Published
Why it matters
Cellular reprogramming has attracted pharma money and billionaire backing, but Life Biosciences is turning the field's core claim into a human safety test.
David Sinclair's Life Biosciences, now run by CEO Jerry McLaughlin, announced Tuesday that it has dosed the first patient in a human trial of ER-100, an investigational cellular reprogramming injection for age-related eye disease, Business Insider reported.
The first patient has glaucoma and received the injection in one eye, according to Business Insider. Life Biosciences did not disclose the patient's identity, the exact dosing date, or additional clinical details. The trial will monitor the patient over six months for safety and early signs of whether ER-100 can restore function.
Sinclair, a Harvard geneticist and Life Biosciences cofounder, is one of longevity science's best-known figures and one of its most disputed promoters. Business Insider noted that Sinclair is no longer involved in day-to-day operations at Life Biosciences, but that his work and ideas helped set up the trial. That matters because ER-100 is not a supplement, a wellness product, or another broad anti-aging promise. It is the first serious test of a much narrower claim: whether partial epigenetic reprogramming can make damaged human cells function better without pushing them into unsafe states.
"We're really looking at the ability to restore function, to reverse disease at a very fundamental level in the body," McLaughlin told Business Insider.
The eye is the proving ground
Life Biosciences is starting with optic neuropathies, not whole-body aging. Business Insider reported that a little under 20 patients are expected in the initial FDA trial, which is recruiting in Boston, New York City, Los Angeles, and Charleston for patients with glaucoma or non-arteritic anterior ischemic optic neuropathy, known as NAION. A ClinicalTrials.gov listing identifies the study as NCT07290244.
That design is as important as the headline. The eye gives Life Biosciences a contained site, measurable functional endpoints, and a smaller safety blast radius than systemic delivery. The ambition behind cellular reprogramming is much larger - muscle, liver, immune cells, and neuronal tissue all sit on the field's wish list - but the first human step is an injection into one eyeball.
Business Insider described the dosing as the first time a reverse-aging treatment has been injected into a human. The narrower, verifiable point is that Life Biosciences has moved a partial cellular reprogramming therapy into human testing, after a field that has been heavy on mouse and monkey data and light on clinical proof.
Why reprogramming draws so much money
The scientific premise traces back to Shinya Yamanaka, who in 2007 showed that adult human cells could be reprogrammed. The proteins associated with that work, often called the Yamanaka Factors, can reset aspects of cellular identity. Longevity companies are chasing a partial version of that reset: enough to make older cells behave more youthfully, not so much that the cells lose their identity or become dangerous.
That balance is the whole bet. Business Insider reported that cellular reprogramming has been linked to cancer in animal trials, a central concern because two of the four original Yamanaka factors are oncogenes. For Life Biosciences, the first job is not proving that aging can be reversed in any broad sense. It is proving that ER-100 can be delivered safely in humans and produce a functional signal in diseased optic nerve tissue.
The timing also reflects where longevity investing has moved. Business Insider reported that New Limit, another cellular reprogramming company, raised a $435 million Series C this month with Eli Lilly participating. Merck Animal Health has put new funding into Rejuvenate Bio, according to the same report. Altos Labs has been backed by Jeff Bezos-linked capital, while Retro Biosciences is associated with Sam Altman.
Life Biosciences' announcement gives that investor narrative something the category has lacked: a human dose. It does not give the category a drug. Business Insider said any therapy in this class is likely more than a decade away from FDA approval, even if early trials work.
Sinclair's long shadow
Sinclair's presence cuts both ways for Life Biosciences. His name helped define the commercial longevity boom, and his Harvard lab made him a magnet for founders and investors chasing interventions that might change the biology of aging. Business Insider also described him as controversial and noted that he has hyped experimental anti-aging treatments that have not met expectations.
That history makes ER-100 a cleaner test than most longevity claims because the trial has to answer to regulators and clinical data, not podcasts, biomarkers, or founder conviction. McLaughlin's pitch is still expansive - reversing disease "at a very fundamental level" - but the next six months are about one patient's eye, safety monitoring, and whether the first signal is strong enough to justify treating more patients.
If Life Biosciences can show function restored without serious safety issues, the result will not validate the broader anti-aging market. It will give cellular reprogramming its first human foothold. If Life Biosciences cannot, the field's most valuable companies will still have to explain why the biology that looks so powerful in animals can be made predictable in people.